Korean J Androl.  2012 Apr;30(1):71-79. 10.5534/kja.2012.30.1.71.

Safety and Efficacy of Bearxat(R)XL Tablet (alfuzosin 10 mg) in Patients with Benign Prostatic Hyperplasia: A Prospective Multicenter Study of Primary Care Clinics

• Lee SJ
• Lee DS
• Choe HS
• Shin MS
• Cho YH

• KMID: 2298812
• DOI: http://doi.org/10.5534/kja.2012.30.1.71

Abstract

PURPOSE
A prospective multi-center study was conducted to evaluate the safety and efficacy of alfuzosin (10 mg), for male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in primary care clinics.
MATERIALS AND METHODS
Three hundred twenty-four patients with complaints of LUTS associated with BPH were enrolled from 17 clinics. Patients received a 12-week course of 10 mg alfuzosin (Bearxat(R)XL Tablet) once daily, and underwent follow-up at 2~4 and 12 weeks post-treatment. The maximum flow rate (Qmax) and residual urine volume (RUV) were measured at each visit. The International Prostate Symptom Score (IPSS), Quality of Life (QoL), and International Index of Erectile Function (IIEF-5) were evaluated at baseline and post-treatment. During the study period, the presence of orthostatic hypotension was evaluated by blood pressure measurement before and after a postural change. Any adverse effects of alfuzosin including retrograde ejaculation were assessed.
RESULTS
Of the 324 enrolled patients, 62 (19.1%) patients dropped out and a total of 262 patients were evaluated. Each value of Qmax, RUV, IPSS, QoL, and IIEF-5 was significantly improved from 14.19+/-8.85 ml/sec, 41.10+/-81.44 ml, 18.04+/-7.36, 3.81+/-0.86, and 11.75+/-6.91, respectively, at baseline, to 15.68+/-6.25 ml/sec, 24.29+/-29.46 ml, 12.19+/-5.59, 2.54+/-0.91, and 12.33+/-7.55, respectively, at end-point. Retrograde ejaculation was found in 2 patients (2/255, 0.78%) at 2~4 weeks and 1 patient (1/152, 0.66%) at 12 weeks. The frequency of orthostatic hypotension was 13.27% (30/226) at baseline, 13.11% (27/206, p=0.8658) at 2~4 weeks, and 14.29% (19/133, p=0.8348) at end-point. The number of patients with adverse events was 36 where the number of adverse events was 60. Among those 60 adverse events, 8 events were related to treatment, which consisted of headache (2), dizziness (2), palpitation (1), voiding difficulty (1), erectile dysfunction (1), and arthralgia (1).
CONCLUSIONS
Treatment with alfuzosin (10 mg) once daily led to significant improvements in LUTS associated with BPH and QoL in primary care clinic patients. alfuzosin (10 mg) use resulted in few hypotensive events, no deleterious effect on sexual function, and no drug related SAEs during the study. The study findings suggest that alfuzosin (10 mg) can be safely prescribed in primary care clinics for male LUTS with efficacy.

Keyword

Prostatic hyperplasia; alfuzosin; Adverse effects

MeSH Terms

Arthralgia
Blood Pressure
Dizziness
Ejaculation
Erectile Dysfunction
Follow-Up Studies
Headache
Humans
Hypotension, Orthostatic
Lower Urinary Tract Symptoms
Male
Primary Health Care
Prospective Studies
Prostate
Prostatic Hyperplasia
Quality of Life
Quinazolines
Quinazolines

Reference

1). Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984; 132:474–9.

2). Fine SR, Ginsberg P. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications. J Am Osteopath Assoc. 2008; 108:333–7.

3). Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006; 176:1529–33.

4). Yoshida M, Kudoh J, Homma Y, Kawabe K. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin Interv Aging. 2011; 6:161–72.

5). Moon DG, Bae YD, Lee SW, Moon KH, Ahn TY, Jeong WS, et al. The efficacy and safety of tamsulosin 0.2mg/day on sexual function in BPH: a multicenter open-label, non-comparative, 3 months ob-servational, phase IV prospective study. Korean J Androl. 2009; 27:123–9.

6). Spilker B. Guide to clinical trials. New York: Raven Press;1991. p. 71–83.

7). Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988; 32:21–6.

8). MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 2005; 66:780–8.

9). Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol. 1995; 154:110–5.

10). Low PA. Prevalence of orthostatic hypotension. Clin Auton Res. 2008; 18:8–13.

11). Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005; 30:173–8.

12). Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol. 1996; 29:29–35.

13). Lepor H. Longterm evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998; 51:901–6.

14). Lee SW, Lee SH, Oh CY, Chung BH. Efficacy and safety of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a 6-months study in real life practice. Korean J Urol. 2009; 50:333–339.

15). Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003; 92:257–61.

16). Chung BH, Lee JY, Kim CI, Kim CS, Oh CY, Lee SW, et al. Sexuality and the management of BPH with alfuzosin (SAMBA) trial. Int J Impot Res. 2009; 21:68–73.

17). Kaplan SA. Side effects of alpha-blocker use: retrograde ejaculation. Rev Urol. 2009; 11:S14–8.

18). Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol. 1966; 38:18–23.

19). Santillo VM, Lowe FC. Treatment of benign prostatic hyperplasia in patients with cardiovascular disease. Drugs Aging. 2006; 23:795–805.